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Sucralfate is a drug that effectively heals duodenal, gastric and oesophageal 
ulcers. It is not absorbed systemically and it has been shown to act locally by coating 
the ulcer base. However when it was also shown to prevent stress ulcers and ethanol-
induced gastric mucosa! lesions, it seemed likely that it acted in some way to improve 
the effectiveness of the gastric mucosa! barrier. Some investigators suggested that it did 
so by stimulating local prostaglandin release. The Slomiany group, on the basis of in 
vitro work on the effects of Sucralfate on pig gastric mucus, claimed that Sucralfate 
acted by altering the physico-chemical properties of mucus to increase the viscosity and 
retard the back diffusion of H + ions. 
The work described in this dissertation set out to verify , in vivo, these claimed 
effects on mucus, using an experimental porcine model of peptic ulceration, the bile 
duct ligated pig. In addition, the effects of Sucralfate were compared with those of 
Famotidine and Misoprostol, and changes in mucous prostaglandins , gastric juice 
pepsin and gastric flora were sought. 
By way of introduction, the known and postulated actions of Sucralfate, 
current understanding of gastric mucus physiology and pathogenesis of peptic 
ulceration , have been reviewed, as have experimental animal models of peptic 




A. GASTRIC MUCOSAL DEFENCES 
Current understanding indicates that the most significant physiological roles of 
the stomach are to accept at intervals relatively large quantities of food, to mix 
components of a meal, to deliver manageable quantities of this prepared food to the 
duodenum, to reduce the bacterial content of ingested material, to detect and eject 
ingested materials which might be harmful to the body, to initiate digestion of protein 
and possibly carbohydrate, to facilitate absorption of certain specific minerals and other 
nutrients and to participate in an intricate interplay of endocrine influences. 1 
The digestive elements of gastric secretions, HCl and pepsin, have the 
potential to digest the gastric epithelium, but under normal circumstances this is 
prevented by a variety of mucosal defence mechanisms acting in concert. The 
components of the mucosal defences are thought to be the mucus layer lining the 
surface epithelium, the bicarbonate ions secreted by the surface epithelial cells, 
interstitial bicarbonate, the mucosal blood flow, the restitutional capacity of surface 
epithelial cells and the hydrophobic property of the surface epithelial cells. 2 
1. MUCUS 
The mucus secretion lining the mucosal surface is a viscous gel with properties 
of both liquid and solid, which may vary in physiological and pathological conditions. 
Mucus from different organs and sites has specialized features to fulfil the special 
function that is required. Normal mucus forms a layer about 0.1-0.5 mm thick, lining 
the internal tracts of the body. It contains inorganic ions typical of extracellular fluids, 
specialized glycoproteins called mucins, several secreted proteins (e.g. immunoglobulin 
A, lysozyme, lactoferrin), and transuded plasma proteins (e.g. albumin) and in some 
mucins, galactose-rich pure polysaccharides. Exfoliated epithelial cell membranes 
contribute glycosphingolipids, phospholipids and various other glycoproteins. The 
organic constituents account for 5-10% of mucus gel weight. 3 
Gastroduodenal mucus exists in two distinct physical forms known as adherent 
mucus, which is a stable gel insoluble in water, and soluble mucus, which mixes with 
the luminal juice 
Adherent mucus adheres to the mucosa! surface in a continuous cover varying 
m thickness from 50 to 450um in humans4 . It provides the stable unstirred layer 
considered necessary to support surface neutralization and provide the mixing barrier 
for luminal acid and mucosa! bicarbonate. It also prevents access of luminal pepsin to 
the underlying epithelial cells. Thickness of the adherent mucus layer can be increased 
by stimulation with prostaglandin E2 and carbachol. 
Soluble mucus mixes with the luminal juice and, being quite viscous, it is an 
excellent lubricant, minimizing physical damage to the adherent mucus gel and 
epithelial cells. It can be removed from the mucosa! surface by gentle washing. It 
contains a greater proportion of lower molecular weight glycoproteins and lower 
concentration of polymeric mucin. It is formed by the mucolytic action of pepsin on the 
luminal surface of the adherent mucus, as well as secretion of polymeric mucin. 
Therefore changes in soluble mucus output do not necessarily reflect changes in 
efficacy of the protective adherent mucus gel. 5 
A) MUCIN STRUCTURE 
The most widely accepted model of the structure of gastric mucin, the 
principal gel-forming constituent of mucus, is that proposed by Allen et a16. This 
model proposes that one subunit of 70 000 daltons is linked by disulphide bonds to 4 
7 
other rigid "bottle-brush" subunits each consisting of a core polypeptide with many 
branched oligosaccharide chains attached. These large "windmill" units may be further 
polymerized into much larger molecules with markedly visco-elastic properties in 
concentrated solution. 
8 
Mucins, comprise 10-15 % protein, constituting the polypeptide core, to parts 
of which are attached hundreds of oligosaccharide chains (the "bottle-brush" regions). 
The cysteine-rich, non-glycosylated regions of the polypeptide cores are believed to be 
the sites of disulphide bridges which link subunits. In the regions of the polypeptide 
core that bear the oligosaccharide chains, serine, threonine, and proline are the 
predominant amino acids . 
The oligosaccharide chains have a typical complement of sugars, including 
galactose, fucose, N-acetyl galactosamine, N-acetyl glucosamine, and negatively 
charged sialic acids. In the case of gastric mucins these chains comprise up to 11-20 
residues and may be branched. Negatively charged sulphate is also a feature of mucins 
- either together with sialic acids or as ester sulphate. Some of the oligosaccharides are 
identical to those found in glycolipids and glycoproteins of red cell membranes which 
confer upon them the antigenic character of the ABO and Lewis systems. Carbohydrate 
comprises 70-85 % of total mass of mucin and the carbohydrates are attached to serine 
and threonine hydroxyl side chains. Because the packing is so close and the tertiary 
structure so tight, the carbohydrate-bearing regions of the protein cores are rather 
resistant to proteases. 
Disulphide bonds cross-link the non-carbohydrate-bearing (naked) regions of 
the polypeptide chains, either to each other or to linker subunits. The oligosaccharide 
side chains are mostly negatively charged and tend to repel each other, forming 
expanded and rigid "bottle-brush" structures. As the concentration of highly hydrated 
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mucins is increased, interdigitating carbohydrate side chains interact by means of 
hydrogen bonds or salt bridges between charged groups, and at concentrations of 20-50 
mg/ml visco-elastic gels are formed. The overlapping domains of extended 
macromolecules cause the entire solvent to become "floppily-solid" so that other 
macromolecules cannot penetrate the interstices of the gel. Small molecules diffuse 
readily through the liquid phase of the gel, although not as freely as in free solution, 
because of ion exchange phenomena and the absence of a stirring mechanism. Purified 
mucins have nearly the same properties as crude mucus when brought to appropriate 
concentrations, and they are believed to be mostly responsible for the physico-chemical 
behaviour. 7 
Proteolysis of non-glycosylated polypeptide regions and/or cleavage of 
disulphide bonds significantly decreases the viscosity of mucus. High salt 
concentrations cause shrinkage of the mucin domains and diminish their entanglement. 
Certain proteins enmeshed in the mucins can enhance gelation, and the lipid 
components probably also have a promoting role in this regard. 
Carlstedt and Sheehan8 have proposed an alternative model of mucin 
structure, in which mucins are built up of a linear array of glycosylated domains 
interconnected by naked protein regions. They believe that mucin subunits are joined 
end-to-end by disulphide bonds to produce linear flexible chains with properties in 
solution approaching those of a random coil. 8,9 
The Slomiany group have proposed a modification of the Allen model 1 O, 
based on their observations that gastric mucins also contain lipid in the form of neutral 
lipids, glycolipids and phospholipids. They have noted differences in the glycolipid 
composition of intracellular and surface mucus, surface mucus having a higher 
proportion of glycosphingolipids which are derived from exfoliated epithelial cell 
membranes, whereas intracellular mucus lipid is almost exclusively 
glucoglycerolipid. 11 It is claimed by these investigators that the glycoprotein polymer 
forms a dynamic continuum with lipids and secreted and transuded proteins and that, 
while mucin is the only component of mucus capable of gel formation, the proteins and 
lipids exert significant effects on the physico-chemical characteristics of gastric mucus . 
2.BICARBONATE 
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Gastric antral and fundal mucosa secretes bicarbonate into the lumen under the 
influence of various stimuli and inhibitory signals. Duodenal mucosa has a similar 
ability to secrete bicarbonate, but the rate of secretion is higher than in the stomach, 
and the processes of transport of bicarbonate and control of secretion differ. 12, l 3 
Bicarbonate secretion has been shown to be considerably greater in the proximal 
duodenum than the distal duodenum, and it seems likely that a substantial proportion of 
acid delivered to the proximal duodenum is neutralized by surface epithelial bicarbonate 
secretion prior to contact with pancreatic or biliary secretions. 14 
Studies using pH-sensitive microelectrodes have shown that pH at the 
epithelial surface is nearly neutral, while that of the luminal solution is 2-3. The mucus 
forms a continuous layer of water-insoluble, visco-elastic gel adherent to the surface 
epithelium. It is not well understood how cells lining the gastric crypts resist acid-
peptic digestion, as only the surface epithelium is covered by mucus. 
Three mechanisms act in concert to control bicarbonate secretion: 
Neural stimulation, together with acid, by the vagi. It can be inhibited 
by anti-cholinergic drugs, and it is thought to be mediated by intracellular c-GMP. 
Local mucosal linkage between the processes of H+ secretion and 
bicarbonate secretion, by parietal cells and surface mucosal cells respectively 
Stimulation of bicarbonate secretion by the presence of acid m the 
lumen. This is probably mediated by prostaglandins, humoral factors, and neural 
mechanisms. Prostaglandin Bi stimulates bicarbonate secretion, more potently when 
administered intraluminally than parenterally. Prostaglandin F2a also stimulates 
bicarbonate secretion but less potently than PG£i. Peptides such as endorphins, VIP, 
and pancreatic polypeptide are also known to stimulate bicarbonate secretion, possibly 
as neurotransmitters. 15 
11 
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B. PATHOPHYSIOLOGY OF PEPTIC ULCER 
The term "peptic ulcer" embraces a number of different categories of 
ulceration of the mucous membrane of the gastrointestinal tract and it is very 
important, in trying to understand their pathophysiology, to be aware of the different 
mechanisms involved. A useful classification is that proposed by Brooks in a recent 
review 16. He recognized two broad groups, viz. acute and chronic. The acute ulcers 
are all gastric and include the ulcers occurring in patients with severe burns and CNS 
lesions, ulcers occurring in patients subjected to severe non-specific stress such as 
shock and sepsis, ulcers occurring after ingestion of aspirin and other non-steroidal anti 
inflammatory drugs (NSAIDs) and excessive ethanol, or exposure to bile reflux, as 
well as ulcers occurring at the extremes of age. The chronic ulcers are subdivided into 
gastric, duodenal, oesophageal, hormonally induced, recurrent after surgery, and those 
adjacent to a Meckel' s diverticulum. The chronic gastric ulcers are further sub-divided, 
as suggested by H. Daintree Johnson 1 7 , into lesser curve ulcers occurring at the 
angulus incisura or, more precisely, at the junction of body and antral mucosae 18 
(Type I); gastric ulcers secondary to duodenal ulceration or scarring (Type II); and 
prepyloric/pyloric channel ulcers (Type III). 
Ulceration in the Zollinger-Ellison syndrome is clearly related to excessive 
gastric acid secretion secondary to uncontrolled gastrin secretion by a gastrinoma. 
Duodenal ulcer disease is associated with high acid secretion in many, but by no means 
all patients and patients with types II and III gastric ulcers have similar acid profiles to 
those with duodenal ulcers. Patients with type I gastric ulcers, however, tend to have 
normal or, more often, lower than normal levels of gastric acid secretion. So acid, 
although clearly important, is not the only factor contributing to ulcer formation. 
Indeed, it is essential to remember that, as Venables has written, "acid has never on its 
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own been shown to induce an ulcer" 19 . Like acid, peptic activity is an indispensible 
component of the pathogenesis of peptic ulcers, even in Zollinger-Ellison syndrome, 
for acid without pepsin has little digestive power, and pepsin is inactive without acid. 
Pepsin, in an acid environment, is a powerful protease that can digest mucus 
and cell membranes, and concentrations of pepsin in gastric juice follow a similar trend 
to acid in the different categories of ulcer. However, analysis of the pepsin profiles in 
normal subjects and patients with peptic ulcers has revealed a higher proportion of total 
peptic activity accountable to pepsin 1 in the gastric juice of ulcer patients - 16.5 % in 
duodenal ulcer (DU) patients and 23 % in gastric ulcer (GU) patients compared with 
3. 6 % in controls20' 21 ' 22 . This may well be significant because, firstly, pepsin 1 has 
been shown to digest mucus more avidly than the other pepsins, and secondly pepsin 1 
retains its peptic activity at higher pH levels (4-5) at which other pepsins are 
inactive. 23 
The mucous membrane of the stomach and duodenum is uniquely adapted to 
resist the corrosive power of acid and pepsin. The adherent mucus gel, whilst being 
digested by pepsin on its luminal surface, is impermeable to pepsin and so protects the 
epithelium from digestion. The adherent mucus also retards diffusion of H+, so 
allowing effective neutralization at the epithelial surface by bicarbonate secreted by the 
epithelial cells. Mucus probably also assists the healing process once epithelial erosion 
has occurred, by acting as a template for fibrinogen-fibrin conversion and preventing 
access of pepsin to the clot25,26. The epithelial cell membranes have an inherent 
resistance to damage by acid and the mucous membrane has the ability to rapidly 
regenerate its epithelium when this is breached. The integrity of this mucosal barrier is 
dependent on adequate blood supply, normal homeostasis and cell metabolism and, 
possibly local prostaglandins27 , and disturbance of this barrier may also contribute to 
ulcer formation. 
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Failure of the mucosal barrier is certainly the primary fault in the genesis of 
acute gastric stress ulcers, acid and pepsin being only secondary co-factors. The 
primary mechanism involves impaired mucosal blood flow, increasing tissue acidosis, 
depletion of ATP and epithelial cell death, with impaired secretion of mucus and 
bicarbonate and consequently increased susceptibility to acid and pepsin, as well as bile 
reflux which may increase as a result of gastrointestinal atonia. Impaired mucosal blood 
flow also results in impaired mucosal restitution. 28 
Peptic ulceration can thus be viewed, perhaps simplistically, as developing as a 
result of disequilibrium between the aggressive factors (acid and pepsin) and the 
defence of the mucosa. However this does not explain why, at a particular time, the 
mucosal defence is weakened to the point that it is overwhelmed by the "aggressors", 
and neither does it explain the typical locations of chronic ulcers 
Whereas chronic gastric ulcers were recorded in ancient history29 , duodenal 
ulceration, although described in the 19th century, only emerged as a common disease 
at the beginning of the 20th century and Wormsley argues, on the strength of this 
observation, for the influence of an "environmental ulcerogen (or deficiencies of anti-
ulcerogenic factors) .. 3o, which allows the initial mucosal damage. He suggests that, 
possibly, a deficiency of epidermal growth factor in saliva or other "growth factors" 
may delay healing of epithelial damage, allowing ulcers to form and become chronic. 
Another suggestion is that gastric and duodenal ulcers are caused by an infectious or 
chemical ulcerogen, herpes simplex virus being proposed as a possible culprit. 
Helicobacter pylori has been proposed as a possible infective cause for peptic 
ulceration31 , although this is controversial32 and it is currently felt to be an important 
co-factor in the pathogenesis of duodenal ulcer disease. This Gram-negative, motile, 
spiral, urease-producing bacterium was first successfully cultured in 1984 and was 
14 
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initially thought to be a member of the Campylobacter family. It is uniquely adapted to 
live in the stomach, immediately above the surface epithelial cells and deep to the 
adherent mucus gel, shielded from the gastric acid to which it is vulnerable after more 
than 30 minutes at pH< 2. Its urease converts urea to ammonia, which also neutralizes 
acid and presumably protects it. It is also found in the duodenal bulb, but only in 
relation to antral-type epithelial cells. In vitro, it is sensitive to numerous antibiotics, 
but in vivo it is resistant to most of them, with the exception of metronidazole and 
tinidazole. This is presumably because of its location deep to the mucus gel, out of 
reach of the antibiotics. Colloidal bismuth subcitrate also exerts anti-bacterial activity 
against the organism. As pathogen, there is good evidence that it causes type B 
gastritis33,34 , but evidence for its role in the aetiology of peptic ulcer disease remains 
circumstantial. Certainly, the current data does not indicate any association with gastric 
ulceration, although the organism is frequently detected in the antra of patients with 
duodenal ulcers, and it may play an indirect role in the development of duodenal 
ulcers. It has been claimed that this organism degrades mucus and in this way initiates 
mucosal damage. 35 This seems highly improbable, given its unique adaptation and 
apparent dependence on the mucus to shield it from the gastric acid. 
In similar vein, Szabo has drawn attention to the similarities m the 
epidemiology of duodenal ulcer disease and Parkinson's disease, and feels that 
"exposure to environmental agents or food products may trigger biochemical defects 
that can result in duodenal ulcer". His experimental work with cysteamine, showing 
deficiencies of dopamine both locally in the stomach and duodenum and centrally in 
parts of the brain, and disorders of duodenal motility, remind us of the importance of 
the brain and motility in the pathogenesis of "peptic ulcer". 36 
C. MODELS OF PEPTIC ULCERATION 
1. IN VIVO 
To date no experimental model of peptic ulceration has been entirely 
satisfactory as none exactly mimics the human disease and they all involve creating 
abnormal physiological circumstances or exposure to highly toxic chemicals. Besides 
this, the human disease is not a uniform single entity, but rather a spectrum of different 
types of peptic ulceration. 
One of the earliest observations of peptic ulcer was the association with acid, 
as indicated by the dictum "no acid , no ulcer" enunciated by Schwarz in 1925, so it is 
not surprising that the earliest animal models involved abnormal exposure of mucosa to 
acid, either by diverting alkaline secretions away from the site of acid exposure, or by 
increasing acid37 ,38 . Other models more closely mimic the acute erosive 
gastritis/stress ulcer syndrome, and several models are themselves poorly understood. 
Some are ingenious experiments, while others were serendipitously discovered in the 
process of other lines of research and subsequently exploited. Yet others involve 
bizarre, unphysiological injuries to the gastric mucosa with e.g. boiling water or 100% 
ethanol, which can have little relevance to clinical practice39 . The following is an 
attempt to classify various ulcer models, but is by no means a complete list of all the 
methods used. 
A) DIVERTING ALKALI 
a) EXCLUSION OF DUODENAL JUICE 
The best known of these is the Mann-Williamson duodenal drainage method in 
dogs , in which the stomach is disconnected from the duodenum, the proximal end of 
16 
duodenum is closed, the proximal jejunum is divided , and the distal end is anastomosed 
to the stomach (end-to-end) and proximal end anastomosed to the ileum end-to-side. 
Other methods include: 
a) transplanting the common bile duct and pancreatic duct to the ileum, which produces 
ulcers in only 50% of the dogs. 
b) the Goldberg method - creating a gastric fistula by anastomosing, in antiperistaltic 
fashion, an isolated piece of small intestine between gastric fundus and skin , and 
subsequent conversion of that segment of fundus to an isolated fundal pouch (in a high 
percentage peptic ulceration occurred in the intestinal mucosa just beyond the gastric 
stoma). 
b) EXCLUSION OF BILE 
The Kapsinow method , which comprises drainage of the gall bladder to the 
renal pelvis and ligation of the common bile duct of dogs , produces ulcers in duodenum 
in 40% within 2 weeks. 
The Bollman and Mann / Berg and Jobling method:- dogs with complete 
obstructive jaundice. About 60% developed perforating gastric and duodenal ulcers. 
c) EXCLUSION OF PANCREATIC JUICE 
The Rous and McMaster method:- complete diversion of pancreatic juice to 
the exterior (in dogs) which produces ulcers in a large percentage. 
In all these models the ulcers heal if the anastomoses are taken down and 
reconnected in the correct sequence, and they confirm the importance of defective 
neutralization of acid in gastric juice. 
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The resistance of duodenum to gastric acid has been demonstrated by the fact 
that only 20% of dogs whose common bile duct and pancreatic duct were transplanted 
to the ileum developed ulcers, and by experiments where duodenal drainage procedures 
were done with preservation of an inch of proximal duodenum and ulceration 
developed at the duodeno-jejunal anastomosis and not in the duodenal remnant. 
B} INCREASING ACID 
a) SHAY'S PYLORUS-LIGATED RAT 
In 1945 Harry Shay and associates accidentally discovered that if rats were 
allowed to survive 18 hours with the pylorus ligated they consistently developed 
perforating ulcers and haemorrhagic glandular ulcers. It soon became the most popular 
experimental model of peptic ulceration because of the ease of preparation, high 
incidence of perforating lesions, and susceptibility to blockade by anticholinergic 
agents. 
18 
Pylorus ligation has been shown to stimulate gastric secretion. The ulcers can 
be prevented by any compound that will reduce either volume or acidity or both of 
gastric juice, as well as compounds that block peptic activity. 
b) DRUGS 
i) GASTRIC STIMULANTS 
Histamine and Gastrin 
Continuous maximal acid output in response to repeated IM or continuous IV 
administration results in duodenal ulcer formation in a high proportion of cases. 
Cinchophen 
Cinchophen (Cl6H11N02) , a drug used in the past for its analgesic and 
antipyretic properties to treat gout40, increases the amount of gastric secretion without 
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altering the level of acidity, when administered by continuous IV infusion or regular 
IM injections, and causes duodenal and gastric ulcers. 
ii) ADRENAL STEROIDS 
Silen points out that it has been accepted as dogma that steroids play an 
important role in stress ulceration, yet almost all studies indicate that steroids 
ameliorate, rather than accentuate stress ulcers and other forms of gastric mucosa! 
damage. 39 
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iii) NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) 
NSAIDS produce a spectrum of gastroduodenal mucosal lesions ranging from 
haemorrhages and petechiae to erosions and ulcers. They probably act systemically by 
inhibition of prostaglandin synthesis, as well as locally to alter the mucosa! barrier, 
either permitting increased H + back diffusion or impairing HC03 - secretion and 
neutralization of acid. The proposed protective role of prostaglandin in gastric 
physiology has been highlighted by the ulcerogenic potential of the NSAIDS. 
The presence of H+ is required to produce ulceration, but it may be that it 
operates by producing the undissociated form of the NSAID, which penetrates the cell 
membrane more easily. It is thought that the cellular damage is caused by the 
dissociated intracellular amon rather than H + itself. 41 Several NSAIDS inhibit 
glycoprotein biosynthesis by the epithelial cells, so although they do not alter the 
secreted mucus gel acutely, they may cause depletion of mucus with chronic use. 42 
Interestingly, acute parenteral injection of aspirin produces acute fundal 
ulcerations, whereas more prolonged injection by chronic intravenous infusion of 
aspirin or indomethacin produces more chronic antral ulcers in cats43 . 
Drug induced ulceration bears little similarity, with the exception of gastrin 




A popular method, recently, of creating gastric mucosal injury, has been 
instillation of 100% ethanol into the stomachs of rats. Ethanol rapidly penetrates the 
mucosa and causes endothelial damage in superficial and deep capillaries and venules, 
resulting in increased permeability and decreased blood flow. This leads to complete 
circulatory standstill in superficial capillaries, so that the direct damage to surface 
epithelial cells is compounded by hypoxia and deep haemorrhagic necrosis in 1-5 
minutes. 44 This is grossly unphysiological, does not require the presence of luminal 
H+, and Silen in a recent editorial review has questioned whether this model has any 
relevance to human disease. 39 
v) INSULIN 
High doses of insulin have been used to induce ulcers in the oxyntic gland area 
of the stomachs of fasted rats. 45 Unlike low doses that stimulate acid secretion, the 
ulcerogenic dose used, 5IU/kg s.c., in addition to causing profound hypoglycaemia, 
suppresses basal and stimulated acid secretion and stimulates gastrin secretion and 
activation of histadine decarboxylase in the gastric mucosa. These ulcers were 
prevented by prior antrectomy, vagotomy or treatment with cimetidine or omeprazole, 
but not by Sucralfate. 
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cl DIRECT APPLICATION OF ACID 
The importance of timing of exposure to acid was demonstrated by 
experiments in dogs that had had HCl infused into the stomach (smaller amounts than 
secreted by normal dogs during digestion) via Mann-Bollman fistulae at a rate of 
lml/minute for 8 hours a day during fasting. The dogs developed chronic gastric ulcers 
along the lesser curve in about 4 weeks. Administration of food during the period of 
infusion was protective. 
Cl HAEMORRHAGIC SHOCK 
This produces acute superficial, haemorrhagic, mucosal lesions, distributed 
mainly in the fundus, with sparing of the antrum. It simulates acute stress ulceration in 
humans, and is as much a model of inadequate tissue perfusion, as it is of specific 
gastric mucosal injury. 
D) CENTRAL NERVOUS SYSTEM MANIPULATIONS 
al STRESSED RA TS 
Rats are stressed by restraint, and other methods, and these rats develop ulcers 
(or, more precisely, erosions, which do not penetrate the muscularis mucosae) in the 
glandular portion of the stomach. Vagotomy and anticholinergic drugs protect the rats 
from developing these lesions. These lesions frequently bleed but do not perforate. 
bl EXECUTIVE MONKEYS 
Experimental psychologists set up behavioural situations usmg operant 
conditioning techniques and compared the incidence of duodenal ulcers in "executive" 
monkeys and non-decision-making "worker" monkeys. The advantage of this model is 
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that it produces duodenal ulcers in primates over several weeks, without surgery, 
drugs, or dietary changes. The disadvantages are that it requires highly trained 
investigators, skilled in designing complex schedules of reinforcement and utilizing 
complex equipment and that the experimental designs are questioned by members of 
animal rights movements 
c) CYSTEAMINE <HSCH2CH2NH2l
According to a recent review36 , the cysteamine-induced duodenal ulcer in rats
has become the most widely used animal model of duodenal ulcer disease. 
Cysteamine is a sultbydryl compound with a variety of biological effects. 46 It
is formed in mammalian tissues by enzymatic hydrolysis of pantetheine4 7 48, and plays
a role in the biosynthesis of hypotaurine. It has been used clinically to treat paracetamol 
poisoning and nephropathic cystinosis, and experimentally as a radioprotective agent. 
That cysteamine invariably causes the development of acute perforating 
duodenal ulcers in rats when administered to these rats either orally or parenterally, 
was a serendipitous discovery by Hans Selye and Sandor Szabo during the course of 
some experiments to study the effect of hormones on resistance to various toxicants49.
The ulceration is associated with increased gastric acid output, delayed gastric 
emptying, and elevated serum gastrin levels, and can be modulated by antacids, 
anticholinergic drugs, histamine receptor antagonists and vagotomy. This model is 
similar to human duodenal ulcer disease in virtually all morphological and functional 
parameters. However, a difference is its frequent association with adrenocortical 
lesions. 
Hormonal changes that follow cysteamine administration include acutely 
increased serum gastrin levels, prolonged suppression of plasma secretin, transient 
depletion of somatostatin in gastric and duodenal mucosa, pancreas and hypothalamus 
and transient elevations of plasma levels of corticosterone, glucagon, insulin and 
glucose. 
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Functional changes induced by cysteamine include greatly increased volume of 
gastric juice, delayed gastric emptying and increased output of alkali. In addition there 
are important alterations in duodenal motility, which may be related to the abundance 
of dopamine binding sites in the muscularis propria. The migrating myoelectric 
complexes are disrupted, the frequency of slow waves is decreased and there are 
changes in intraluminal pressure and transit time. The net effect is faster transit from 
proximal to distal duodenum and slower passage from distal duodenum to duodenal 
bulb. 36 
d) PANTOTHENIC ACID DEFICIENT ZUCKER RATS 
This model has been known for many years but not widely used because of the 
need for the special strain of rat and the slow development of the lesions, which are 
associated with villous atrophy, duodenitis and erosions progressing to ulceration. Acid 
output is first decreased, but in subsequent weeks is increased. The intriguing feature of 
this model is the biochemical relationship to the cysteamine model, pantotheine being 
the naturally occurring molecular combination of pantothenic acid and cysteamine, and 
an intermediate in the pathway of coenzyme A. 
e) OTHER SULFHYDRYL COMPOUNDS 
Duodenal ulcers were also noted to develop after administration of 3,4-
toluene-diamine and propionitrile, although these were less acute and less consistent. 
. 
Subsequently n-butyronitrile, a molecule closely related to propionitrile, was identified 
as a more rapid duodenal ulcerogen with lower toxicity than propionitrile. 50 
Propionitrile induces duodenal ulcers that are morphologically identical to those 
induced by cysteamine but, unlike cysteamine, does not deplete tissue somatostatin or 
elevate serum gastrin, but does decrease alkaline secretion in the duodenum while only 
transiently and sporadically increasing acid and pepsin. 
Other related chemicals which are weak ulcerogens are acetanilide and 3,4 
toluene-dithiol. Mepirazole is another compound which induces acute and chronic 
duodenal ulcers which are superficial and accompanied by gastric erosions and 
ulcers. 50 
E) MECHANICAL FACTORS 
24 
The observation that ulcers always formed at the point of impact of the ejected 
acid with the mucous membrane led to experiments aimed to establish whether a 
mechanical factor was important in determining the site of the ulcer: 38 
in the Mann-Williamson model, straightening out the segment receiving 
the acid so that the expelled gastric juice runs in the same direction for about 12cm, 
resulted in the ulcers forming at a point just proximal to where the loop bends acutely, 
and not just beyond the line of anastomosis 
slightly altering the axis of the pylorus in Mann-Williamson model dogs, 
when one ulcer had already formed, resulted in the formation of kissing ulcers 
deliberately making the stoma between pylorus and intestine narrow, 
after a duodenal drainage procedure, to create a "nozzle-like action", resulted in the 
ulcers developing more quickly and perforating earlier. 
transplantation of vascularized patches of jejunum into the wall of the 
stomach (Morton), resulted in ulceration of the patch only very rarely. 
dogs with complete obstructive jaundice developed duodenal ulcers more 
rapidly if fed a diet of dog biscuits and bones than if fed milk and syrup 
F) ECK FISTULA 
Dogs with a simple Eck fistula (side-to-side porto-caval shunt) frequently die 
from perforated duodenal ulcers. The mechanism, however, is not clear51 . 
G) PHYSICAL INJURY 
Grossly unphysiological insults such as application of boiling water and 
concentrated alkali have been used to create gastric mucosa! injury. Unlike most in vivo 
models of gastric mucosal injury, this model does not require the presence of luminal 
H+. 
H) BILE DUCT LIGATED PIG 
a) HISTORY 
Spontaneous perforating and bleeding oesophago-gastric ulcers in pigs, once 
an agricultural curiosity, is now a significant problem in the swine industry, with 20 -
50% of pigs coming to slaughter having these lesions51 ,52,53 . The ulcers have been 
attributed to nutritional and environmental factors , as the incidence can be modified by 
changing the diet and not housing in small enclosures with slanting floors, as was the 
common practice54•55 . 
These ulcers also complicate experimental surgery on pigs, with a histological 
incidence of 80 % and mortality from haemorrhage of 50-60 % in survivors of 
orthotopic liver transplantation, as well as liver autografts 56,57 . This ulceration was 
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noted to be associated with cholestasis, and ligation of the bile duct reproduced the 
ulcer with 100% reliability58,59 . Although bile duct ligation itself is lethal in the pig, 
highly selective vagotomy done at the same time as bile duct ligation, significantly 
prolongs survival and completely eradicates the problems of ulceration of the pars 
oesophagea 60 . 
b) INVESTIGATION 
Arnot studied changes in Heidenhain pouches following bile duct ligation and 
found increased basal acid secretion, decreased response to histamine, and increased 
response to pentagastrin at low doses, though not at high doses. He deduced that the 
increased basal secretion was not likely to be due to increased parietal cell sensitivity or 
decreased hepatic degradation of pentagastrin, but was possibly due to absence of a 
circulating inhibitor or increased amounts of a circulating secretagogue. Gastrin levels 
were measured and found to decrease after bile duct ligation, the lowest levels being 
noted within 48 hours. These returned to normal by the 5th day after bile duct ligation. 
Gastrin was thus clearly not the stimulus to the gastric hypersecretion. 58 
Watson found that exogenous gastrin aggravated the oesophago-gastric 
ulceration following bile duct ligation, and concluded from studies with total gastric 
fistulae that the hypersecretion was not due to gastrin, calcium, abnormality of liver 
function or absence of bile from the stomach. He confirmed that bile duct ligation 
causes greatly increased volume and concentration of acid secretion and also showed 
that antral secretion was decreased but more alkaline. From this he deduced that the 
alkali was insufficient to neutralize the acid, or the ulceration was not entirely due to 
acid hypersecretion, and suggested that bile duct ligation diminished inhibition of acid 
secretion or stimulated secretion of a "non-gastrin secretagogue" (? entero-oxyntin). 
Further investigations showed that bile duct ligation was followed by increased serum 
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levels of several amino acids, infusion of plasma from bile duct ligated pigs into pigs 
with total gastric fistulae caused gastric hypersecretion (up to 14x greater than plasma 
from sham operated pigs), infusion of plasma from bile duct ligated and sham operated 
pigs into rats had similar effects, and electron microscopy of gastric cardia and pars 
oesophagea revealed degranulation of mast cells in bile duct ligated stomachs but not 
sham operated stomachs. The conclusion from these studies was that the ulceration of 
the pars oesophagea of pigs whose common bile duct has been ligated, could be 
attributed to an active gastric secretagogue. 61 
C) ANATOMICAL FEATURES OF THE PORCINE STOMACH 
The pig stomach has several anatomical differences from the human stomach. 
Firstly, there is the pars oesophagea, which is a rectangular, 2xlcm, area of stratified, 
non-keratinized, squamous epithelium at the cardiac entrance of the stomach, 
immediately distal to the oesophagus and distinct from oesophageal epithelium. 
Secondly, the fundus is relatively much larger, and the lesser curve relatively much 
shorter than those of the human stomach. Then, unlike the arrangement in the human, 
the common bile duct enters the first part of the duodenum a few millimeters distal to 
the pylorus on the anti-mesenteric aspect, separate from the pancreatic duct which 
enters several centimeters further distally on the inner aspect of the duodenal curve, and 
bile refluxes freely into the stomach. Finally, the pylorus looks very different, having a 
bulbous structure, the torus pylori, which projects into the lumen from the lesser curve 
aspect. 
d) PORCINE GASTRIC MUCUS 
The viscous and gel-forming properties of gastric mucus depend on the 
polymeric structure of the undegraded glycoprotein, which is a polymer of four 
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subunits of equal size joined by disulphide bridges located between the carbohydrate-
free parts of the protein core of each subunit. 62 The undegraded glycoprotein from 
human gastric mucus has been shown to have the same size, polymeric structure, and 
overall properties as that in pig gastric mucus. 63 
2. IN VITRO 
Using isolated sheets or sacs of mucosa allows investigators to control the 
many variables that bedevil in vivo models , and to dissect the intimate intracellular 
biochemical events that lead to cell death and ulceration . However, a sheet of organized 
surface cells cannot simulate the interactions between surface and oxyntic cells , and 
these systems are also hampered by the fact that cells can only be assessed as viable or 
non-viable, since simple functions attributable to surface cells are almost impossible to 




Peptic ulcer treatment has for decades been based on the principle of reducing 
available acid in the gastric juice and since the mid 1970's has been dominated by the 
Hz-receptor antagonists. However, another group of drugs that had no effect on gastric 
acid proved to be as effective as the H2-receptor antagonists, cimetidine and ranitidine 
and came to be known as "cytoprotective agents" or "site-protective agents", because 
they appeared to strengthen the mucosal barrier. 64,65 
One of these agents is Sucralfate, a basic aluminium salt of sucrose 
octasulphate which has proved to be significantly better than placebo, and as effective 
as cimetidine and ranitidine in short term healing of duodenal and gastric ulcers66,67 . 
Marks et al have also shown lower recurrence rates of duodenal ulcers after healing 
with sucralfate than after healing with cimetidine. 68 This phenomenon has been 
confirmed by Lam et al 69 , although disputed by other studies 70' 71 . Maintenance 
therapy in a dose of 2g nocte, also is as effective as Hz-receptor antagonists in 
preventing relapses of both gastric and duodenal ulcers. 72, 73, 74 Doses of lg b.d. have 
also proved to be effective maintenance therapy for duodenal ulcer patients. 75, 76 In 
addition, Sucralfate protects the gastric mucosa against injury by ethanol 77, 78, 79 and 
aspirin80, and is now regarded as the drug of choice for stress ulcer prophylaxis28, 
being more effective than Hz-receptor antagonists and at least as effective but more 
convenient than antacids. Also, sucralfate has some inherent antibacterial activity81 
and, because it does not increase pH, is less prone than Hz-receptor antagonists and 
antacids to allow bacterial overgrowth, which by way of reflux of gastric contents 
predisposes to nosocomial pneumonias in mechanically ventilated patients. 82,83,84 
The effectiveness of Sucralfate was at first ascribed to coating of the ulcer 
base. 85 Mixed with HCl, sucralfate polymerizes to form a sticky, viscous paste and a 
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white paste-like substance was noted to adhere selectively to ulcerated and eroded 
gastric mucosa, and was thought to prevent diffusion of protons and pepsin. Other 
properties ascribed to the drug and thought to contribute to its mechanism of action 
were adsorption of pepsin and adsorption of bile salts. 86 
30 
However, the effectiveness in preventing recurrent gastric and duodenal 
ulcers, stress ulcers and alcohol-induced gastric mucosal injury, suggests a more 
complex mechanism involving the mucosal defences. There has been much interest in 
possible prostaglandin mediation of increased mucus and bicarbonate secretion 78,87 
and improved mucosal blood flow , but the effectiveness in preventing aspirin-induced 
mucosal injury makes it likely that other mechanisms are involved88, and in a recent 
study prostaglandin could not be linked mechanistically to increased mucus secretion in 
rats protected from ethanol-induced gastric mucosal injury by sucralfate. These 
investigators also noted that although mucus secretion was stimulated by sucralfate, 
mucus synthesis was not. 89 Currently it is agreed that while prostaglandins may 
contribute to the protective effects of sucralfate, other mechanisms are also 
involved. 90,91 It has also been suggested that the protective effect of sucralfate may 
involve epidermal growth factor (EGF) by binding EGF and carrying it to the ulcer. 92 
Changes in gastric mucus have also been proposed to account for the 
protective effect of Sucralfate. In healthy human volunteers, Sucralfate tablets were 
seen to disperse and adhere firmly to a relatively small area of mucosa where striking 
histological and ultrastructural changes occurred in the surface epithelial cells. Mucus 
granules were discharged and a thick mucus layer formed over the mucosal surface. 
Cells separated from the basal lamina, vacuoles appeared in the cytoplasm and nuclei 
enlarged. 93 The Slomiany group from New York have suggested that the protective 
effect of sucralfate is due to inhibition of peptic degradation of mucus glycoprotein and 
binding of sucralfate with the mucus glycoprotein to enhance the viscosity and improve 
the capacity of the mucus to retard H+ diffusion. These investigators extracted gastric 
mucus from pig stomachs, obtained from the local abattoir, by filling the stomachs with 
2M NaCl solution buffered to pH 7.0, and then dialyzing and lyophilizing the instillate. 
The extracted mucus was subsequently mixed with different concentrations of 





To attempt to verify the claimed effects of Sucralfate on viscosity and 
retardation of hydrogen ion diffusion of porcine gastric mucin, in vivo, using the bile 
duct ligated pig model 
II. 
To assess the effectiveness of Sucralfate in the prevention of oesophago-gastric 
ulceration in the bile duct ligated pig model. 
Ill. 
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To compare the effects of Sucralfate with those of Misoprostol (an analogue of 
Prostaglandin E1) and Famotidine (a long-acting Hi-receptor antagonist) on oesophago-
gastric ulceration and mucus viscosity and H + diffusion in the bile duct ligated pig 
model. 
IV. 
To assess the effects of Sucralfate, Famotidine and Misoprostol on 
prostaglandin concentrations in gastric mucus, gastric flora , gastric juice pH, and 




Experiments were performed on Landrace X Large White pigs weighing 
between 20 and 30 kg and aged 8-12 weeks. The pigs were starved (except for water) 
for 24 hours before surgery. The pigs were assigned to one of two large groups: bile 
duct ligation or sham. Each of these groups contained four subgroups receiving 
different test drugs: 0.9% physiological saline; Sucralfate; Misoprostol; and 
Famotidine. Each subgroup consisted of seven pigs. 
35 
Anaesthesia was induced with intravenous thiopentone (2-3 mg/kg) and 
maintained with 0 2 and nitrous oxide administered via a cuffed Portex endotracheal 
tube. 
An incision was made in the neck and the internal jugular vein was cannulated 
for fluid administration. Midline laparotomy was then performed and a small 
gastrotomy made in the anterior wall of the distal 1/ 3 of the stomach. The mucous 
membrane of the stomach was swabbed for bacteriological culture and gastric juice was 
collected for subsequent pH and pepsin estimation. The first dose of the test substance 
was inserted in the stomach through the gastrotomy and a large bore Foley catheter, 
after being passed through a stab incision in the lateral abdominal wall, was then placed 
in the stomach and fixed with two purse-string 2/ 0 silk sutures after inflating the 
balloon of the catheter and pulling it up to the wall of the stomach. Those pigs 
allocated to a bile duct ligation group, then had the bile duct ligated and divided. The 
abdominal wound was then closed and the corked Foley catheter was fastened with a 
skin suture, as far dorsally as possible to prevent the pigs from biting the catheters. 
Thereafter, the pigs were returned to individual cages in a warm environment 
and were given free access to drinking water. Intravenous Maintelyte (SABAX) 
infusions were continued for approximately 24 hours. During the 48 hours after the 
operation, the test substances were administered down the Foley catheters at strictly 6 
hourly intervals for Sucralfate (lg), saline(30ml), and Misoprostol(200ug). Famotidine 
(40mg) was given once daily. 
Forty eight hours after the initial surgery, the pigs were re-anaesthetised in 
similar fashion and total gastrectomy performed before the animals were sacrificed. 
The pyloric and oesophageal ends of the stomachs were firmly ligated before removal. 
Gastric juice was again collected for estimation of pH and pepsin. The stomachs were 
then drained completely and food residue washed out with tap water, before being 
filled to capacity (2.5-3L) with 2M NaCl-lOmM sodium phosphate buffer pH 7.0. 
After 30 minutes the instillate was collected in glass bottles, and the stomachs were 
opened along the greater curve to: a) inspect for macroscopic evidence of ulceration; b) 
excise the pars oesophagea for histology; c) swab the mucous membrane for culture; 
and d) scrape off residual mucus with a glass slide for prostaglandin assay. 
B. MUCUS EXTRACTION 
The retrieved gastric instillate was filtered, first through glass wool and then 
through a bottle top vacuum filter fitted with a Schleicher & Schuell GF92 glass fibre 
prefilter. The filtrate was then dialysed in No. 4 Spectra/por cellulose dialysis tubing, 
against distilled water for about two days to remove all the NaCl. Dialysis was done in 
a refrigerator at 4°C. The dialysate was partially dried in a rotary evaporator and then 
lyophilised. The dry mucus powder was collected, weighed and stored in glass bottles 
at -20°C. 
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C. PROSTAGLANDIN ESTIMATION 
Prostaglandin E was estimated by radioimmunoassay in mucus scraped off the 
mucosa! surface of the stomach after the 2M saline instillate had been drained from the 
stomach. The scraped mucus was frozen in liquid nitrogen immediately after collection 
and stored at -20°C. 
The mucus sample was thawed and added to 1ml O.OlM phosphate buffered 
saline pH 7.4 (PBS) and 3ml extraction solvent, 3:3: 1 (v/v) Ethyl acetate : Isopropanol 
: O. lN HCl in an all glass Potter Elvjhem homogenizer and homogenized. The 
homogenous suspension was transferred to a glass stoppered centrifuge tube, the 
homogenizer was then rinsed with 2ml ethyl acetate and then 3ml distilled water, and 
these were both then transferred to the centrifuge tube, which was then shaken 
continuously for 15 minutes and then centrifuged for 10 minutes at 3000 r.p.m. The 
separated aqueous phase was kept for assay of protein. The supernatant phase was 
transferred to a conical test tube containing approximately 250mg NaHC03 and 250 mg 
Na2S04 and well mixed on a vortex mixer. The solvent was then evaporated to dryness 
under a stream of Nitrogen and the residue dissolved in 1ml of a 60:40 (v/v) benzene : 
ethyl acetate solvent (Solvent I) while still under N2. The tube of extract was covered 
with parafilm and stored at -20°C until chromatography was performed. 
To prepare the chromatography column, Silicic acid (SIL-A -200 60-200 
mesh) was placed in a shallow dish and heated for at least one hour in an oven at 
110°C, then taken out and placed in a beaker containing 10ml Solvent I. The slurry 
was transferred to a glass column with rinsing, and was washed with 15ml Solvent I, so 
that the column of Silicic acid had a faint blue tinge and was completely translucent. 
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The extract was transferred to the column and the tube was rinsed several 
times with Solvent I which was also added to the column. The column was then eluted 
with another 5ml of Solvent I. This eluate of approximately 12ml contained 
Prostaglandins A & B (PGA and PGB) and was discarded. Thirty millilitres of Solvent 
II (Benzene : Ethyl acetate : Methanol :: 60:40:3 v/v) was then applied to the column 
and eluted at about 2ml/min. This eluate, which contained PGE, Thromboxane B2 and 
6-keto PGF1a, was evaporated to dryness under a stream of N2 and then 1ml 0.1 % 
bovine serum albumin in PBS (PBSA) was added while still under nitrogen. Then the 
sample was transferred to a small stoppered Teflon tube covered with a stream of N2 
and stored at -20°C until required for the radioimmunoassay. 
To assay for Prostaglandin E, 0.1ml of sample or standard were pipetted into 
assay tubes. A zero control, a blank and a total tube each containing 0.1ml PBSA were 
prepared. One half millilitre rabbit anti-prostaglandin E-BSA serum (Miles-Yeda Ltd. 
K.iryat Weizman, Rehovot, Israel) were added to all tubes except the total and blank 
tubes. To these were added 0.5ml buffer. All tubes were incubated at 4°C for 30 
minutes, then 0.1ml tritiated Prostaglandin E standard (160Ci/mmole supplied by 
Amersham Ltd and diluted with buffer to 100 000 degradations per minute/ml) was 
added to all tubes and they were incubated at 4°C for 60 minutes. Then 0.2ml dextran 
coated charcoal solution was added to each tube except the total tube, to which 0.2ml 
buffer was added. All the tubes were mixed on a vortex mixer, incubated at 4 °C for 
10 minutes, then centrifuged at 4°C at 3000 r.p.m. for 15 minutes. An aliquot (0.5ml) 
supernatant was removed and added to 6ml scintillation fluid (Picafluor or Instagel, 
Packard Instruments Ltd) and counting was done in a liquid scintillation spectrometer. 
The fraction bound was calculated by the formula: 
% fraction bound = cpm in sample - cpm in blank x 100 
cpm in zero ctr) - cpm in blank 
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centrifuged at 4°C at 3000 r.p.m. for 15 minutes. An aliquot (0.5ml) supernatant was 
removed and added to 6ml scintillation fluid (Picaflour or Instagel from Packard 
Instruments Ltd) and counting was done in a liquid scintillation spectrometer. 
The fraction bound was calculated by the formula: 
% fraction bound = cpm in sample - cpm in blank x 100 
cpm in zero ctr) - cpm in blank 
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A standard curve was obtained using a working dilution of the antiserum and 
plotting % bound vs concentration. Values of unknown samples were obtained from the 
curve and PGE concentrations calculated allowing for dilutions. 
Working dilutions were prepared by first preparing a stock solution of 1mg 
PGE2/100ml absolute ethanol, then diluting 1ml stock in 100ml PBSA. The first 
dilution was diluted again 1ml: 10ml PBSA to give a concentration of lOng/ml. Then 
further serial doubling dilutions were prepared in buffer to give standard 5, 2.5, 1.25, 
0.63, 0.31, and 0.15 ng/ml solutions. 
D. VISCOSITY MEASUREMENT 
Thirty milligrams of the dry mucus powder was dissolved, with constant 
stirring at room temperature for 12-24 hours, in 1ml O. lM NaCl-0.05M Na2HP04 
buffer (pH 6.0) to which was added lul of phenylmethanosulphonyl fluoride (PMSF), 
an inhibitor of proteolysis. Viscosity of 0.5ml samples was measured with a Brookfield 
cone/plate digital viscometer, model LVTD, equipped with a CP40 cone and constant 
temperature (37°C) water bath, at shear rates of 45, 90, 225 and 450 s-1. Several 
readings were taken at each shear rate and the means calculated. The 1.565° cone used 
by the Slomiany group was found to be unsuitable for our samples. 
39 
A standard curve was obtained using a working dilution of the antiserum and 
plotting % bound vs concentration. Values of unknown samples were obtained from the 
curve and PGE concentrations calculated allowing for dilutions. 
Working dilutions were prepared by first preparing a stock solution of 1mg 
PGE2/100ml absolute ethanol, then diluting 1ml stock in 100ml PBSA. The first 
dilution was diluted again 1ml: 10ml PBSA to give a concentration of lOng/ml. Then 
further serial doubling dilutions were prepared in buffer to give standard 5, 2.5, 1.25, 
0.63, 0.31, and 0.15 ng/ml solutions. 
D. VISCOSITY MEASUREMENT 
Thirty milligrams of the dry mucus powder was dissolved, with constant 
stirring at room temperature for 12-24 hours, in 1ml O. lM NaCl-0.05M Na2HP04 
buffer (pH 6.0) to which was added lul of phenylmethanosulphonyl fluoride (PMSF), 
an inhibitor of proteolysis. Viscosity of 0.5ml samples was measured with a Brookfield 
cone/plate digital viscometer, model LVTD, equipped with a CP40 cone and constant 
temperature (37°C) water bath, at shear rates of 4.5, 11.25, 22.5, 45, 90, 225 and 450 
s-1. Several readings were taken at each shear rate and the means calculated. The 
1.565° cone used by the Slomiany group was found to be unsuitable for our samples. 
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E. HYDROGEN ION BACK DIFFUSION 
A Perspex apparatus, similar to that described by Sarosiek et al96 was 
constructed (Figure I). The chamber on one side of the centre panel was filled with 
0.15M HCl and the other chamber with 0.15M NaCL The sample port, with a capacity 
of 150µ1, was separated from the two chambers (350ml each) by two millipore 
membrane discs (pore size 0.45µm). This apparatus was incorporated within a closed 
chamber which was connected by an inlet and an outlet port to a thermostatically 
controlled water heater-cum-pump. The test solutions were thus continuously 
surrounded by circulating water at 37°C. 
The samples were prepared by dissolving 30mg dry mucus powder in 1ml 
0.15M NaCl with constant stirring for 12-24 hours. One microlitre Phenyl methan 
sulphonyl fluorid (C7H70 2SF) (PMSF) was added to the sample. 
The test sample was placed in the sample port first. Then the NaCl and HCl 
solutions, prewarmed to 37°C, were poured simultaneously into their respective 
chambers. The solutions were continuously agitated with magnetic stirrers, and kept at 
a temperature of between 37 and 38 °C. 
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The pH of the NaCl solution was continuously monitored with an electrode 
connected to a Radiometer pH meter. Recordings were made of the time taken for each 
change of 0.1 pH units. The rate of H+ movement into the NaCl solution was then 
calculated by dividing the difference in hydrogen ion concentration by the number of 
seconds taken for the pH to change that 0.1 unit. 
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Photographs of the apparatus for measurng Hydrogen ion diffusion. Two chambers are separated by a panel containing the sample port, which is filled via a small channel drilled down the centre of the panel. The solution chambers are covered with a well -fitting lid which has holes for thermometers on each side and for the pH probe on the NaCl side. The solutions are surrounded on the sides by a separate compartment through which water is continuously circulated by a thermostatically controlled heater pump. On top of the water bath compartment are the stainless steel discs and rubber O rings which hold the millipore filters across the openings of the sample port. 
F. CHROMATOGRAPHIC ANALYSIS 
Thirty milligrams of dry mucus powder was dissolved in 1ml 0.10M NaCl-
0.05M Na2HP04 buffer (pH 6.0), with lul PMSF added. Chromatography was done 
on a 100 x 1.5cm Sepharose 2B column, using the PAS method (Mantle & Allen 1978) 
for carbohydrate estimation and Biorad method for protein estimation of the fractions 
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G. PEPSIN 
Gastric juice pepsin activity was assayed by the Berstad modification 1 02 of 
the method of Anson 1 Ol, which uses acidified (pH 1.8) human haemoglobin as 
substrate. After incubating diluted, acidified, gastric juice samples with haemoglobin 
for precisely 10 minutes, 0.3N trichloro-acetic acid (TCA) was added to stop the 
reaction (by precipitating protein). A blank was prepared in similar fashion, except that 
TCA was added in advance. TCA-soluble split products in the filtrate were read in a 
spectrophotometer at 280um against the blank and a standard made from crystalline 
Pepsin at a concentration of 30mg/ml. 
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A. INCIDENCE OF ULCERATION 
In the 4 sham groups only two pigs (one in the Famotidine group and one in 
the Misoprostol group) had some macroscopically evident superficial ulceration of the 
pars oesophagea. Microscopic examination revealed occasional superficial ulceration or 
inflammation. 
In the bile duct ligation groups all pigs treated with NaCl and Famotidine, and 
6 out of 7 treated with Misoprostol had oesophago-gastric ulceration. These ulcers were 
usually deep and in many cases had caused haemorrhage. However, of those treated 
with Sucralfate, only two of the seven had ulceration on macroscopic observation. 
These observations are summarized in Table I below. Figure II depicts this graphically. 
TABLE I: 
NUMBER OF ANIMALS WITH GASTRO-OESOPHAGEAL ULCERS 
SCR Fam Mis NaCl SQR 
No. of pigs 7 7 7 7 7 7 7 7 
Macro:ulcer 0 0 0 1 7 0 7 5 
erosion 0 0 1 0 0 2 0 1 
normal 7 7 6 6 0 5 0 1 
Micro:ulcer 0 0 0 1 3 1 5 3 
erosion 1 2 1 1 2 1 1 2 
regen. 0 1 0 0 0 3 0 0 
normal 4 3 4 3 0 2 0 1 
inflam. 0 1 2 2 0 0 0 1 
The difference in ulcer rate in the bile duct ligation peptic ulcer model animals 
given Sucralfate, compared with those given saline, Famotidine or Misoprostol was 
statistically highly significant (p < 0.01) and provided clear evidence of a protective 
effect of Sucralfate. 
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The details of macroscopic appearances of the stomachs and histological 
reports of biopsies of the pars oesophagea of individual pigs are listed in tables II and 
III below. 
Table II 
269 No ulcer Not biopsied 
338 No ulcer Normal 
417 No ulcer Normal 
432 No ulcer Normal 
450 No ulcer Normal 
498 No ulcer Healing erosions of sq. epith. 
543 No ulcer Normal 
SUCRALFATE 
268 No ulcer Not biopsied 
349 No ulcer Normal 
415 No ulcer Erosions of sq. epithelium 
447 No ulcer Healing erosion & regeneration 
448 No ulcer Normal 
499 No ulcer Normal 
556 No ulcer Inflammation in sq. epith. mucosa 
FAMOTIDINE 
444 No ulcer Normal 
465 No ulcer Normal 
475 No ulcer Inflammation in sq. epith. mucosa 
495 No ulcer Focal inflammation 
520 No ulcer Normal 
582 No ulcer Normal 
605 Small erosions Erosions of sq epithelium 
MISOPROSTOL 
538 No ulcer Inflammation in sq. epith. mucosa 
558 No ulcer Normal; mild inflammation 
562 No ulcer Normal 
572 No ulcer Submucosal inflammation 
575 Small ulcer Junctional ulcer 
604 No ulcer Junctional erosions 





























































Erosions of sq. epithelium 
Deep ulcer into m. propria 
Erosions of sq. epithelium 
Extensive ulcer into m. propria 
Flat junctional ulcer 
Extensive flat ulcer 
Not biopsied 
Ulcer in Sq.epith. - to submucosa 
Normal 
Normal 
Junctional erosions; regeneration 
Regenerative activity only 
Regeneration Sq. ep.; Gastritis 
Junctional ulcer into m. propria 
Flat ulcer & erosion in sq.epith. 
Deep ulcer into serosal fat 
Flat ulcer in sq. epithelium 
Superficial erosions of body 
Extensive flat ulcer sq.epith. 
Flat ulcer into submucosa 
Junctional flat ulcer & erosions 
Junctional flat ulcer & erosions 
Squamous epithelial erosions 
Junctional submucosal abscess 
Junctional ulcer into m.propria 


















































563 Bleeding ulcer 
569 Erosionss-pars&bod y 
576 Huge ulcer 
606 Superficial ulcer 
608 No ulcer 
Not biopsied 
Erosions of sq. epithelium 
Deep ulcer into m. propria 
Erosions of sq. epithelium 
Extensive ulcer into m. propria 
Flat junctional ulcer 
Extensive flat ulcer 
Not biopsied 
Ulcer in Sq.epith. - to submucosa 
Normal 
Normal 
Junctional erosions; regeneration 
Regenerative activity only 
Regeneration Sq. ep.; Gastritis 
Junctional ulcer into m. propria 
Flat ulcer & erosion in sq.epith. 
Deep ulcer into serosal fat 
Flat ulcer in sq. epithelium 
Superficial erosions of body 
Extensive flat ulcer sq.epith. 
Flat ulcer into submucosa 
Junctional flat ulcer & erosions 
Junctional flat ulcer & erosions 
Squamous epithelial erosions 
Junctional submucosal abscess 
J unctional ulcer into m. propria 





The mean prostaglandin levels with standard deviations, standard errors of the 
means and 95 % confidence limits for the eight treatment groups are listed in Table IV 
and the the relationships between mucus prostaglandin levels in the various treatment 
groups have been depicted in a simple bar graph, Figure III and a notched box and 
whiskers plot (Statgraphics), Figure Illa on the following page. Individual 
prostaglandin levels for each pig are shown in the Appendix. 
TABLE IV: 
PROSTAGLANDIN IN SCRAPED GASTRIC MUCUS ( 
Mean 272.714 261.57 
SD 123.347 212.15 
SALINE SEM 46.621 80.187 
95% conf 91.377 157.16 
Mean 280.714 209.42 
SD 82.164 127.89 
SUCRALFATE SEM 31.055 48.338 
95% conf 60.868 94.743 
Mean 214.143 237.14 
SD 86.964 113.26 
FAMOTIDINE SEM 32.869 42.807 
95% conf 64.424 83.902 
Mean 119.714 119.29 
SD 36.468 40.165 
MISOPROSTOL SEM 13.784 15.181 
95% conf 27.016 29.755 
Calculated with Statgraphics 5. 0 software using the Mann-Whitney test for 
comparing two unpaired samples, there was no statistically significant difference in 
prostaglandin levels between the saline treated sham and BDL groups. There was also 
no significant difference between the shams given saline and those given Sucralfate, 
Famotidine, or Misoprostol. The animals given Misoprostol tended to have lower 
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and the difference between the bile duct ligation groups given saline and Misoprostol 
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C. VISCOSITY 
Five or six readings were taken on each specimen at each of the shear rates of 
450, 225 and 90 per second. Viscosity readings at 45 per second were very 
inconsistent, so usually only 2 or three readings were taken at this shear rate. Mean 
values (plus SD and SEM) were calculated for each specimen at each shear rate. The 
total and mean of all the readings at each shear rate in each group were also calculated. 
The mean viscosity was calculated for each specimen at each shear 
rate. The means of the means were then calculated for each shear rate in 




MEAN 120.14 128.05 135.18 129.51 
SD 15.78 19.89 35.42 45.35 
SEM 5.96 7.52 13.39 17. 14 
225/sec .. 
MEAN 127.58 135.79 143.2 136.32 
SD 18.58 23.32 39.67 51.85 
SEM 7.02 8.82 14.99 19.6 
90/sec 
MEAN 141.71 148.85 161.81 144.92 
SD 19.4 31.77 62. l 62.6 
SEM 7.33 12.01 23.47 23.66 
. 45/sec 
MEAN 162.4 178.19 166.38 164.85 
SD 47.49 89.27 46.44 65.13 




MEAN 97.98 170.7(121.3) 103.19 125.76 
SD 11.78 136.6(39.17) 13.74 11.62 
SEM 4.45 51.64(15.98) 5.19 4.39 
>225/sec 
MEAN 101.37 183.1(127.4) 107.34 135.67 
SD 15. 1 153 . 1(45.35) 18.08 19.54 
SEM 5.71 57.88(18.52) 6.83 7.39 
90/sec 
MEAN 106.86 200.95(138.67) 111.61 145.03 
SD 20.18 171.25(51.04) 19.59 30.66 
SEM 7.63 64.73(20.84) 7.4 11.59 
45/sec 
MEAN 102.8 264.18(152.2) 134.07 170.41 
SD 42.49 253.5(89 . 13) 57.93 88.01 
SEM 21 .25 117.74(51.46) 23 . . 65 33.27 
There was a statistically significant difference (Mann-Whitney) between the 
viscosity of mucus from saline-treated shams and saline-treated bile duct ligation 
animals (two-tailed probability of equalling or exceeding Z = 0.0298). The mean 
viscosity of the Sucralfate-treated bile duct ligated pigs was distorted by the mucus of 
one pig, No. 500, which had very high viscosity readings at all shear rates. On 
sacrificing this pig it was noted that the bulb of the Foley catheter had obstructed the 
pylorus and the whole stomach was lined by a white film (presumably Sucralfate, on 
the surface of, or mixed with the mucus). In the table above, therefore, calculations 
excluding the readings from this pig are listed in parenthesis. However there was no 
statistically significant difference between the treatment groups and the saline controls 
in the sham operated animals, or between Sucralfate and Famotidine bile duct ligation 
51 
groups and the saline control bile duct ligation group. Misoprostol, however, did 
enhance the viscosity of the mucus with respect to the saline controls in the peptic ulcer 





D. HYDROGEN ION DIFFUSION 
The data from the hydrogen ion diffusion experiments is depicted in Figures V 
and VI. 
The graphs were plotted using Sigmaplot version 3.1 software. Rate of 
Hydrogen ion diffusion (permeability) has been plotted against time in seconds. The 
dotted lines depict 5th order regression curves of the data from mucus samples from 
each pig in a particular group. The solid line is a 5th order regression curve of the 
graph as a whole (i.e. the mean of the seven curves in each graph). 
With 0.155M NaCl in the sample port, the permeability curve has an initial 
fairly steep slope followed by a plateau phase for about an hour and then a steep slope 
again. With reconstituted mucus samples in the sample port the level of the plateau 
phase was of a similar magnitude, but was prolonged. 
There was very little difference between the shams and bile duct ligated pigs 
given saline, and very little difference between any of the sham treatment groups. 
However, it appeared that the rate of H+ diffusion was, if anything, slower in the bile 
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On Sepharose 2B gel chromatography, protein (measured by Biorad kit) eluted 
as two well defined peaks, an excluded peak (V 0) and an included peak (Vi). The 
former represents mainly intact glycoprotein whilst the latter consists of low molecular 
weight glycoprotein and protein (e.g. albumin, IgA etc.) The carbohydrate in the eluted 
fraction was detected by the PAS method (Mantle & Allen 1978) and, as above, the 
crude mucus eluted as two well defined peaks. The included peak was the result of 
interference from the high protein content 
The mean percentages and standard deviations in the VO fractions by the PAS 
and Biorad methods are listed in Table VII and depicted graphically in the bar chart in 
figure VI. Individual values can be found in the appendix 
TABLE VII 
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PAS BIORAD PAS BIORAD 
SALINE Mean 37.86 38.86 23.86 24.29 
SD 11.91 14 3.53 6.99 
SEM 4.5 5.29 1.34 2.64 
SUCRALFATE Mean 39.41 45.71 28.71 36.29 
SD 15.64 19.37 10.66 20.72 
SEM 5.91 7.32 4.03 7.83 
FAMOTIDINE Mean 24.43 33.14 22.43 22.14 
SD 3.46 17.34 3.41 9.81 
SEM 1.31 6.56 1.29 3.71 
MISOPROSTOL Mean 26.71 19.86 22.43 18.43 
SD 2.06 8.36 3.6 5.68 
SEM 0.78 3. 16 1.36 2.15 
Calculated with Statgraghics version 5.0, using the Mann-Whitney test for 
comparison of unpaired samples, there was a significantly lower percentage, with both 
PAS and Biorad methods, of VO (intact mucus glycoprotein) in the bile duct ligation 
control group than in the sham operated controls. The 2-tailed probability of equalling 
or exceeding Z was 0.0298 for the PAS data and 0.047 for the Biorad data. 
In the sham groups, those treated with Misoprostol had significantly lower 
percentages of Vo (PAS and Biorad) than the saline controls. The famotidine treated 
animals also tended to have lower percentages of Vo than controls and Sucralfate 
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F. PEPSIN AND PH OF GASTRIC JUICE 
The pH of the gastric juice was measured at the initial gastrotomy, before any 
treatment, in 43 pigs. The mean pH was 3.55 (range 6.84 - 1) with standard deviation 
(SD)= 1.564 and standard error of the mean (SEM) = 0.238. 
Gastric juice pepsin activity was measured in 37 pigs before treatment. The 
mean pepsin was 61.9 mg% (5-138) with SD = 31.7 and SEM = 5.2. 
Mean pepsin and pH values of gastric juice at the time of sacrifice after 
treatment are displayed in Tables VIII and IX and depicted graphically in Figure VIII 
TABLE VIII 
mrm > scR 
pH Peps pH Peps pH Peps pH Peps 
Number 5 5 5 7 7 7 7 
Mean 3.8 64.1 3.47 43.6 4.32 54.9 3.25 37 
SD .84 31 1.7 21.5 1.06 36.3 1.6 18.4 
SEM .38 13.9 .76 9.6 .4 13.7 .6 6.9 
95% conf .74 27.1 1.49 18.8 .78 26.9 1.18 13.6 
99% conf .97 35.7 1.96 24.8 1.03 35.4 1.56 18 
There appeared to be some reduction in pepsin in the shams after treatment 
with each of the three drugs, but the differences were not statistically significant. Bile 
duct ligation, on the other hand , tended to cause an increase in gastric juice pepsin, but 
this was also not statistically significant. 
Gastric juice pH did not change after treatment with Sucralfate or Misoprostol 
but did increase a little after treatment with Famotidine. After bile duct ligation there 
was a decrease in gastric juice pH of saline controls compared with pre-treatment pH, 
59 
which approached statistical significance. (Mann-Whitney test for comparing two 
unpaired samples; Statgraphics version 5. 0) 
TABLE IX 
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pH Peps pH Peps pH Peps pH Peps 
Number 4 4 5 5 7 7 7 7 
Mean 2.11 104.2 3.16 63.0 2.7 76.2 1.66 72.1 
SD 0.5 71.5 1.61 65.4 1.04 55.2 .44 35.3 
SE 0.25 35.8 .72 29.3 .39 20.8 .17 13.3 
95% conf 0.49 70.1 1.41 57.4 .77 40.9 .33 26.2 
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G. BACTERIOLOGY 
From Tables X & XI, it is clear that the stomach of the pig is usually 
colonized with a variety of organisms, the most frequently isolated in this study being 
Escherichia coli (E.coli), Enterococci and Diphtheroids. Yeasts were also often 
cultured. These cultures were of swabs taken of the stomach at gastrotomy and no 
nasogastric tube had been inserted prior to surgery. Of 48 stomachs swabbed at the 
initial gastrotomy, 19 yielded E. coli, 7 Diphtheroids, 6 Staphylococcus epidermidis, 8 
Enterococcus, 4 Candida albicans and 5 "other yeasts". Usually the growth was light, 
but occasionally there was a moderate or heavy growth. Helicobacter pylori was not 
cultured in any pig stomach in this series. 
Cultures of swabs taken at the time of sacrifice are obviously bedevilled by 
contamination, as the gastrostomy had been present for 48 hours. However, it is still 
valid to make comparisons of different treatments in the sham and bile duct ligated 
groups and comparison of sham with bile duct ligation for each treatment, assuming 
that the potential for contamination was the same in all groups. 
There was virtually no difference in the cultures of those pigs having sham or 
bile duct ligation when treated with saline, except that two of the shams had moderate 
growths and one had a heavy growth, whereas only one bile duct ligated pig had a 
moderate growth and all others were light growths. 
Of 5 shams and 5 BDLs treated with Sucralfate and cultured, there were 4 
organisms cultured in the BDL pigs and 6 in the shams; there were 3 moderate growths 
and no heavy growths in the BDL pigs, and among the positive cultures from the shams 
there was one heavy growth and the other 5 were light. 
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1 + Yeasts 
2 + E.coli; 1 + Enterococ 
1 + Enterococcus 
1 + Yeasts 
No growth 
1 + E.coli; 1 + Enterococ 
No growth 
1 + Diphtheroids 
1 + E.coli 
1 + Staph. epiderm.; 
1 + Bacillus sp. 
Yeasts (not C.alb) 
1 + Bacillus sp.; 
1 + Proteus mirab; 
1 + a-haem. Strep 
1 + E.coli 
1 + Staph. epidermidis 
1 + Klebsiella sp. 
1 + E.coli 
No growth 
1 + Candida albicans 
1 + Diphtheroids 
1 + Staph. aureus 
3 + E.coli; 1 + Diphther 
1 + Staph. epiderm.; 
Not cultured 
Not cultured 
2+ E.coli; 2+ Enterobacter; 2+ yeasts 
1 + Candida; 1 + Enterobacter sp. 
2 + E.coli; 1 + Diphtheroids 
3 + Non-fermenting Gram neg bac; 1 + E.coli; 
1 + 13-haem. Strep(grpA) 
2 + mixed organisms 
Not cultured 
Not cultured 
1 + Yeasts 
3 + Enterobacter sp. 
1 + Staph. epidermidis 
3 + Non-fermenting Gram neg bac; 1 + E.coli; 
1 + 13-haem.Strep{grpA) 
2 + mixed orgs 
2 + Klebsiella sp. 
1 + Citrobacter diversus; 2+ Diphtheroids 
1 + Klebsiella; 1 + Candida 
2+ E.coli; 2+ a-haemolytic Strep; 1 + Yeasts (not C. Albicans) 
1 + Staph. aureus; 1 + E.coli; 1 + Enterobacter sp. 
1 + 13-haem. Strep.(not grp. A) 
3 + Klebsiella sp.; 3 + E.coli 
1 + Klebsiella sp.; 1 + E.coli; 1 + Enterococci; 1 + Proteus 
mirabilis 
3 + E.coli; 3 + Enterobacter sp.; Yeast; 1 + 13-haem. Strep.(grp.G) 
3 + E.coli; 3 + Enterobacter sp. ;3 + Pseudomonas aeruginosa 
3 + E.coli; 1 + Enterobacter sp.; 1 + fl-haem. Strep. (grp. C) 
1 + E.coli; 1 + Acinetobacter sp.; 1 + Staph. aureus 
1 + E.coli; 2+ Micrococcus sp. 
1 + Candida albicans 
2+ E.coli; 2+ Klebsiella sp. 
63 
Swabs were taken from the stomachs of all the pigs treated with Famotidine 
and Misoprostol. From the pigs treated with Famotidine, there was a total of 15 
isolates in the bile duct ligation group and 18 in the sham group. In the bile duct 
ligation group only one growth was heavy and one moderate, whereas in the sham 
group five were moderate and two heavy. From the pigs treated with Misoprostol, 
there was a total of 21 isolates in the bile duct ligation group and 18 in the sham group. 
However, all the growths in the bile duct ligation group were light, whereas in the 
shams there were 6 heavy and 3 moderate growths. 
TABLE XI 
271 Not cultured 
345 Not cultured 
419 1 + E.coli 
430 2 + Diphtheroids; 
1 + Enterococci; 1 + E.coli 
1 + Staph. aureus 
452 3 + E.coli; 1 + Enterococ 
496 No growth 
553 1 + E.coli; 1 + Klebsiella sp. 
272 Not cultured 
347 Not cultured 
418 1 + Diphtheroids 
429 1 + Bacillus sp. 
449 No growth 
500 1 + Enterococ; 1 + yeasts 
550 1 + Staph.epiderm. ; 
1 + Enterobacter sp 
1 + E.coli; 1 + Proteus 
Not cultured 
Not cultured 
2 + Enterobacter sp. 
1 + Candida albicans 
No growth 
1 + E.coli; 1 + a-haem. Strep. ; 1 + yeasts (not C. albicans); 
2+ Non-fermenting Gram neg bac 




2+ Clostridium sp. 
No growth 
2+ E.coli; 1 + a-haem. Strep. 
2 + mixed organisms 
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All the pigs treated with Famotidine and Misoprostol had swabs taken. From 
the pigs treated with Famotidine, there was a total of 15 isolates in the bile duct 
ligation group and 18 in the sham group. In the bile duct ligation group only one 
growth was heavy and one moderate, whereas in the sham group five were moderate 
and two heavy. From the pigs treated with Misoprostol, there was a total of 21 isolates 
in the bile duct ligation group and 18 in the sham group. However, all the growths in 




271 Not cultured 
345 Not cultured 
419 l + E.coli 
430 2 + Diphtheroids; 
1 + Enterococci; 1 + E.coli 
1 + Staph. aureus 
452 3 + E.coli; 1 + Enterococ 
496 No growth 
553 1 + E.coli; 1 + Klebsiella sp. 
SUCRALFATE 
272 Not cultured 
347 Not cultured 
418 1 + Diphtheroids 
429 1 + Bacillus sp. 
449 No growth 
500 1 + Enterococ; 1 + yeasts 
550 1 + Staph.epiderm.; 
1 + Enterobacter sp 




2 + Enterobacter sp. 
1 + Candida albicans 
No growth 
1 + E.coli ; 1 + a-haem. Strep.; 1 + yeasts (not C. albicans); 
2 + Non-fermenting Gram neg bac 




2 + Clostridium sp. 
No growth 
2+ E.coli; l + a-haem. Strep. 
2 + mixed organisms 
64 
FAMOTIDINE 
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443 2+ E.coli 
466 1 + E.coli; 1 + Enterococ 
478 1 + E.coli; 1 + Enterococ 
494 1 + E.coli; 1 + Yeast 
521 No growth 
580 1 + Strep.m.it.; 1 + E.coli; 
603 1 + Diphther; 1 + E.coli; 




548 1 + Staph. epiderm.; 
1 + Candida albicans 
559 1 + Staph. epiderm.; 
563 1 + E.coli 
569 No growth 
576 No growth 
606 1 + Diphtheroids 
608 1 + E.coli; 
2 + anaerobic G + bac. 
TABLE XII 
SHAMS 
No. pigs cultured 
Total no. isolates 
Heavy growths 
Moderate growths 
BILE DUCT LIGATED PIGS 
No.pigs cultured 
Total no. isolates 
Heavy growths 
Moderate growths 
1 + Klebsiella; 1 + Enterobacter sp. 
1 + Citrobacter freundii; 1 + Diphtheroids 
1 + E.coli; 1 + Proteus sp.; 1 + Bacillus sp.; 
1 + Enterococci; 1 + Diphtheroids 
3 + E.coli; 2+ Enterococci 
1 + B-haem. Strep. (not grp. A) 
1 + E.coli; 1 + grp.A B-haem. Strep 
1 + E.coli 
1 + Staph. aureus; 1 + E.coli; 1 + Enterococci; 
1 + Enterobacter 
··' .. 
. .. .. . ·· ... •/ 
·. 
1 + B-haem. Strep. (grp A); 1 + Enterococcus; 1 + E.coli; 
1 + Enterobacter sp. 
1 + Staph.aureus; 1 + Enterobacter; 1 + a-Haemolytic Strep. 
1 + Staph. aureus; 1 + E.coli 
l+ E.coli 
1 + Staph. aureus; 1 + E.coli; 1 + Clostridium; 
1 + Acinetobacter; 1 + B-haem. Strep 
1 + E.coli; 1 + B-haem. Strep 
SALINE SCR FAM 
5 5 7 
11 7 18 
1 1 2 
3 0 5 
SALINE sue FAM 
5 5 7 
8 5 15 
0 0 1 














A. THE BILE DUCT LIGATED PIG MODEL 
It is acknowledged that the bile duct ligated pig is not an ideal model of chronic peptic 
ulceration, the ulcer being located at the oesophago-gastric junction in squamous 
epithelium, which is clearly different from the human situation. However, no ideal 
model of human peptic ulcer disease has yet been found and, with the possible 
exception of the cysteamine model, all other models have little similarity to the 
naturally occurring chronic peptic ulcer diseases of humans and are useful only in 
trying to dissect isolated aspects of the pathogenesis to attempt to understand the 
pathophysiology in its entirity. Advantages of this pig model are that (a) it is a naturally 
occurring phenomenon of economic significance to the pig farming industry, that can 
be reproduced with 100 % reliability by ligating the common bile duct; (b) it is 
associated with gastric hyperacidity which appears to be hormonally mediated by either 
an endocrine or paracrine means, with additional vagal influence; (c) the gastric mucus 
of pigs is similar to that of humans; and (d) the volume of mucus that can be retrieved 
from a pig stomach allows individual analysis of mucus of experimental animals rather 
than pooling mucus from several animals which would be necessary if other (smaller) 
models were used. Furthermore, as this study set out to verify the claimed in vitro 
effects of Sucralfate on pig gastric mucus, it is appropriate to use a pig model for the in 
vivo study. 
B. THE METHOD OF MUCUS COLLECTION 
Acknowledged investigators in the field of mucus research disagree on the 
optimal method of mucus collection for scientific analysis. The majority hold the 
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opinion that the surface mucus is the relevant mucus and that the mucus glycoprotein is 
exclusively responsible for the physico-chemical propertes of mucus. This school 
believes, therefore, that only the purified mucus glycoprotein that has been extracted 
from surface mucus scraped off the epithelium, should be studied. The Slomiany group 
have a different philosophy, based on their data which suggest that intracellular mucus, 
which differs from surface mucus particularly in its lipid content, also contributes to 
the gastric mucosal barrier, and the protein, lipid and other glycoproteins associated 
with the mucus glycoprotein do contribute to the physico-chemical properties of mucus. 
The method of instilling hypertonic saline into the stomach followed by 
filtration and dialysis is employed by Slomiany group to collect both surface and 
intracellular mucus. The possibility that the high salt concentration may diminish 
entanglement of mucin molecules is clearly an important objection to this method of 
collection. The other major criticism of the Slomiany group's methods is that they do 
not purify the mucus glycoprotein because of their belief that mucus should be studied 
as a whole rather than being dissected into components. 
In this study the methods of the Slomiany group have been followed because 
the objective was to verify their in vitro experiments with an in vivo model. The study 
was designed to include several controls in the form of sham-operated animals and 
saline treated animals, so that, despite the reservations , the comparisons between 
various treatment groups were felt to be valid 
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C. THE EFFECTS OF SUCRALFATE ON GASTRIC MUCUS 
1.PREVENTION / HEALING OF ULCERATION AT THE PARS OESOPHAGEA 
The most striking, and obviously significant, observation made in this study 
was the beneficial effect of Sucralfate in preventing the ulcers, which hitherto had only 
been prevented by highly selective vagotomy. Because of the study design of sacrificing 
after 48 hours, it is not possible to comment on whether Sucralfate prevents 
oesophago-gastric ulcer formation or whether it allows rapid early restitution of the 
mucosa after ulceration commences. However, it is in line with the clinical experience 
with stress ulceration, and certainly suggests a more complex mechanism of action than 
simply acting as a physical barrier in an ulcer crater. A subsequent study in our 
laboratory has shown prevention of ulceration after seven days. 
2. EFFECTS ON MUCOSAL PROSTAGLANDIN 
Hollander et al suggested that the mechanism by which Sucralfate heals and 
prevents ulcers may be by stimulating prostaglandin release77 . 
Prostaglandins are thought to enhance mucosal defences by stimulating 
bicarbonate secretion, increasing mucus secretion, improving mucosal blood supply and 
accelerating surface epithelial restitution. Prostaglandin analogues, such as Misoprostol, 
also inhibit acid secretion. 
Prostaglandins are ubiquitous molecules which are notoriously difficult to 
study because they are released after any injury to cell membranes. This is why many 
deductions about prostaglandins, including those of Hollander et al in this context, are 
inferred from indirect circumstantial evidence where a known effect is prevented by a 
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drug (e.g. Indomethacin) which is known to inhibit prostaglandin. It is well known, of 
course, that anti-prostaglandin drugs readily produce gastric ulceration themselves, so 
inferrential deductions such as these with respect to the mechanism of action of 
Sucralfate, must be viewed with circumspection. 
As an adjunct to studying the effects of Sucralfate on mucus it was decided to 
study prostaglandin E in scraped mucus to see if there were any differences between the 
various treatment groups. 
There was a very wide scatter of prostaglandin levels. There was no significant 
difference detected between the saline controls having sham operations or bile duct 
ligation, which suggested that Prostaglandin secretion/release was not an important 
response to injury in this peptic ulcer model. It was interesting that endogenous 
prostaglandin appeared to be suppressed by Misoprostol. There was possibly a trend to 
slightly lower prostaglandin levels in the bile duct ligation groups treated with saline 
and Sucralfate and certainly no stimulation of prostaglandin by Sucralfate 
While the study design allowed for comparison between different groups, the 
method of collection of material for assaying prostaglandin remains a difficult problem. 
Simply handling the stomach in the process of performing the gastrectomy may be 
enough to release prostaglandins and certainly distending the stomach with hypertonic 
saline and then scraping residual mucus off the epithelium is a major insult to the 
epithelial cells. Whether surface mucus is the best place to measure prostaglandin is 
also questionable, but taking epithelial biopsies for measuring prostaglandin, produces 
I 
similar cell trauma and is therefore open to the same criticism 
EFFECTS ON MUCUS VISCOSITY 
Viscosity is the measure of the internal friction of a fluid. This friction is 
apparent when a layer of fluid is made to move in relation to another. The force 
required to cause this movement is called shear and shear stress is the force per unit 
area (dynes/cm2). Shear rate is the speed at which intermediate layers of fluid move 
with respect to each other and the unit of measurement is the "reciprocal second" 
(sec-1). Viscosity is calculated by dividing shear stress by shear rate and the 
fundamental unit is poise. (1 poise or 100 centipoise (cps) = 1 dyne.sec/cm2 which is 
equivalent to 10 Pascal-seconds) 
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Newtonian fluids have a viscosity, at a given temperature, which is 
independent of shear rate, the relationship between shear stress and shear rate being a 
straight line. However most fluids are non-Newtonian and viscosity changes as the 
shear rate is varied. Therefore the viscometer model, spindle and speed all have an 
effect on the measured viscosity. Non-Newtonian fluids may exhibit one of several 
types of flow behaviour viz pseudoplastic, dilatant or plastic. Pseudoplastic behaviour 
is decreasing viscosity with increasing shear rate, whereas dilatant behaviour is 
increasing viscosity with increasing shear rate. Plastic flow implies that the fluid 
requires a certain force to be applied before any flow is induced and once this yield 
force is exceeded and flow begins, the fluid may exhibit Newtonian, pseudoplastic or 
dilatant flow characteristics. Thixotropic and rheopectic behaviour refers to changes in 
behavior with passage of time, the former being a decrease in viscosity with time (at 
constant shear rate) and the latter an increase with time. 
Viscosity implies the existence of laminar flow, the movement of one layer of 
fluid past another with no transfer of matter from one to the other. Beyond a certain 
maximum speed, transfer of mass occurs and flow becomes turbulent, resulting in 
erroneously high viscosity readings. The point at which turbulence occurs depends on 
the velocity at which the layers move, the viscosity and specific gravity of the material 
and the geometry of the spindle and sample container of the viscometer. 
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Factors which will affect the rheological properties of fluids are the 
temperature, shear rate (with non-Newtonian fluids), measuring conditions, time (with 
thixotropic and rheopectic fluids), previous treatment of the fluid (eg. pouring, stirring, 
mixing etc.), composition and additives and the state of aggregation and shape of 
particles in emulsions and dispersions. Measuring conditions which may influence 
viscosity readings are the viscometer model, the spindle/speed combination, the sample 
container size, the sample temperature and preparation technique, the ambient 
atmosphere and the homogeneity of the sample. 
It is clear from the foregoing discussion that measurement of viscosity requires 
very carefully controlled conditions. The many intermediary steps used to prepare the 
reconstituted mucus samples may have compromised the accurate measurement of 
viscosity. 
Despite the fact that mucus was collected and reconstituted by the same 
methods described by the Slomiany group, the readings obtained with the type of cone 
used by these investigators were excessively high so the viscometer had to be fitted 
with a different cone and the plate was reground accordingly. 
The mean viscosities of all samples were higher at shear rates of 45 and 90 
/second, than at 225 and 450 /second indicating that the mucus behaved as a non-
Newtonian fluid. The standard deviations of readings were, however, also much larger 
at the lower shear rates, suggesting that these readings were less reliable than those at 
225 and 450/sec. 
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Comparing mucus viscosity in the saline controls, it is apparent that viscosity 
is reduced in the peptic ulcer model. Misoprostol appeared to prevent the loss of 
viscosity in the peptic ulcer model. Sucralfate was not shown to have any significant 
effect on the viscosity of mucus in shams or the peptic ulcer model 
EFFECTS ON RATE OF HYDROGEN ION DIFFUSION 
Hydrogen ions diffused across the reconstituted mucus samples from the HCI 
solution to the NaCl solution, at a more or less constant rate after an initial lag phase, 
as can be seen from the 5th order regression curves plotted in figures V & VI 
The curve depicting diffusion across the mucus from saline-treated bile duct 
ligated pigs was slightly steeper than that for shams treated with saline, suggesting that 
mucus from bile duct ligated pigs might be a little less efficient at retarding H+ 
diffusion. However, there was no difference in rate of H+ diffusion between the 
differently treated sham operated pigs. 
Hydrogen ion diffusion experiments in this study have not convincingly shown 
any significant retardation of H + diffusion and certain! y, there were no significant 
differences between the various groups studied. 
EFFECTS ON MUCUS DEGRADATION 
There was a slightly greater percentage of intact mucm m mucus from 
Sucralfate treated sham operated animals than shams given physiological saline. There 
was significantly less intact mucus in saline treated animals subjected to bile duct 
ligation than in those having sham operations, suggesting that there 1s increased 
degradation of mucus in the ulcer model. Treatment with Sucralfate appeared to inhibit 
degradation of mucin (or stimulate secretion) in the ulcer model, as the difference in 
percentage of intact mucin between shams and bile duct ligation groups treated with 
Sucralfate was less than with the respective saline treated groups. Treatment with 
Famotidine or Misoprostol, if anything, appeared to favour degradation of mucin. This 
may well have been related to the greater bacterial overgrowth noted in these groups. It 
was also notable that bacterial colonization appeared to be inhibited in the animals 
given Sucralfate. However, bacterial overgrowth does not seem to be the only factor, 
because in the bile duct ligated groups there was not much difference between the 
treatment groups in the number of moderate to heavy growths. 
EFFECTS ON GASTRIC ACID AND PEPSIN ACTIVITY 
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The average pH of gastric juice was higher than would be expected in normal 
human stomachs. This is probably due to the free reflux of bile into the stomachs of 
pigs. Famotidine treated animals had the highest mean pH but the differences between 
groups was not statistically significant. There was also no significant difference in 
levels of pepsin activity between the different sham operated treatment groups 
Ligation of the bile ducts significantly reduced the gastric juice pH in saline 
treated animals and there was a corresponding increase in pepsin activity. The 
differences in gastric juice acidity and pepsin activity between shams and bile duct 
ligated animals was less notable in the other treatment groups 
Wide scatter of readings with large standard deviations from the means made it 
impossible to draw any conlusions from these data. It must be noted that the method 
used to measure pepsin activity was simple and, perhaps, in the light of the current 
knowledge of the complex nature of gastric pepsin, rather crude. 
VI. CONCLUSIONS 
The bile duct ligated pig is a useful experimental peptic ulcer model, 
particularly for the study of mucus physiology. 
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Sucralfate proved to be a highly effective agent in the prevention of peptic 
ulceration in this model. However, no definite conclusions have been reached about its 
possible mechanism of action. It did seem that Sucralfate may inhibit the breakdown of 
gastric mucin. It also seemed to inhibit bacterial colonization and gastric juice pepsin 
activity and one could speculate on how these observations inter-relate. The possibility 
that Sucralfate promotes the physical attributes of mucus, could not be verified in this 
study and this study could not substantiate the claims that Sucralfate may exert its 
therapeutic effect by stimulating gastric mucosa! prostaglandin release. 
This study did not address the question of Sucralfate binding to growth factors 
such as epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF), 
which have been shown to stimulate angiogenesis in and greatly accelerate healing of 
experimental ulcers, as well as having high affinity for Sucralfate. 97,98,99 It has been 
suggested that Sucralfate, by its affinity for these growth factors inhibits their 
degradation by gastric luminal acid and by its affinity for damaged mucosa concentrates 
the growth factors at the ulcer site. 1 OO 
It should be stressed that all aspects of measurement in this study were 
complicated and also readily influenced by a number of factors. This, together with the 
variability of any biological model of healing and the small numbers of animals would 
account for the lack of positive findings. Nevertheless, it should also be borne in mind 
that subsequent studies and the wealth of clinical data demonstrate a beneficial effect of 
Sucralfate treatment on healing of ulcers. Possibly the principal mechanism is not 




APPX 1: PROSTAGLANDIN E LEVELS IN SCRAPED MUCUS 
Pig pg/ml Pig pg/ml 
269 172 271 725 
338 241 345 124 
432 420 419 167 
SALINE 417 432 430 150 
450 331 452 297 
498 193 496 213 
543 120 553 155 
268 299 272 158 
349 301 347 459 
415 293 418 150 
SUCRALFATE 447 282 429 112 
448 413 449 305 
499 239 500 170 
556 138 550 112 
444 214 443 283 
465 226 466 366 
475 358 478 261 
FAMOTIDINE 495 235 494 374 
520 250 521 149 
582 96 580 131 
605 120 603 96 
562 116 563 175 
558 154 548 114 
538 173 559 164 
MISOPROSTOL 572 83 576 81 
575 69 569 67 
604 118 606 130 
607 125 608 104 
APPX 2a: MUCUS VISCOSITY DATA 



















































































































































































































































































APPX 3: CHROMATOGRAPHY DATA 
PIG PAS VO(%) 
••. $AUNE 
269 39 54 271 28 28 
338 50 48 345 26 32 
432 14 18 419 27 22 
417 41 37 430 24 16 
450 32 23 452 23 16 
498 44 52 496 21 33 
543 45 40 553 18 23 
SUCRA.LFATE 
268 14 37 449 21 20 
349 64 82 272 23 40 
415 51 50 347 31 53 
447 37 18 418 31 10 
499 40 41 429 14 21 
448 31 41 500 47 69 
556 37 51 550 34 41 
FAMOTIDINE 
444 23 17 443 20 12 
465 23 33 466 20 27 
475 25 29 478 23 29 
495 23 68 494 29 30 
520 31 39 521 24 33 
582 26 29 580 19 9 
605 20 17 603 22 15 
MlSOPROSTOL 
558 27 12 548 29 25 
538 26 16 563 20 10 
562 27 20 559 18 18 
572 25 25 569 23 12 
575 26 17 576 24 19 
604 25 13 606 23 21 
607 31 36 608 20 24 
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